^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    pritumumab (CLNH 11)

    i
    Other names: CLNH 11, ACA 11, CLN-IgG
    Associations

    News

    Trials
    Company:
    Nascent Biotech
    Drug class:
    VIM inhibitor
    Associations

    News

    Trials
    11ms
    Characterization of pritumumab in murine models and primate safety study. (PubMed, Sci Rep)
    Overall, these data together suggest pritumumab is biologically active and animal models can be used to further understand the various functions of the antibody. Clinical trials in brain cancer patients assessing safety and efficacy of pritumumab as a therapeutic for brain cancer are in process.
    Preclinical • Journal
    |
    VIM (Vimentin)
    |
    pritumumab (CLNH 11)
    12ms
    Cell surface vimentin: a natural human immune response target for immunotherapy. (PubMed, Front Mol Med)
    One of these vimentin-reactive antibodies, pritumumab, has been used to treat brain cancer patients. This review summarizes data on mAbs reactive with cell surface vimentin and their origin from lymph nodes of cancer patients.
    Review • Journal
    |
    VIM (Vimentin)
    |
    pritumumab (CLNH 11)
    1year
    Safety Study of Pritumumab in Brain Cancer (clinicaltrials.gov)
    P1, N=15, Completed, Nascent Biotech | Recruiting --> Completed | N=42 --> 15
    Trial completion • Enrollment change
    |
    pritumumab (CLNH 11)
    over5years
    Unconventional immunotherapy with an unconventional target. (PubMed, Hum Antibodies)
    A clinical trial assessing higher doses of pritumumab as a therapeutic for brain cancer is expected to begin this year. Overall, these data together suggest pritumumab is suitable for further development as an anti-tumor therapeutic.
    Review • Journal
    |
    VIM (Vimentin)
    |
    VIM expression
    |
    pritumumab (CLNH 11)